Two immunomodulating polysaccharides, poly-( 1-6 )-b-glucotriosyl-( 1-3 )-b-glucopyranose (PGG)-glucan and Bacteroides fragilis polysaccharide A (PS A), were evaluated for the prevention of mortality and abscess formation associated with experimental intraabdominal sepsis. Prophylactic treatment with a combination of these compounds significantly reduced mortality (8% vs. 44% in the saline-treated control group) and the incidence of abscesses (30% vs. 100% in the saline-treated control group) after challenge with rat cecal contents. These compounds were also effective when administered therapeutically after bacterial contamination of the peritoneal cavity. PS A treatment conferred long-term protection against abscess formation and resulted in significantly fewer total aerobes and anaerobes in the peritoneal fluid of animals challenged with cecal contents. These data demonstrate the usefulness of two immunomodulatory polysaccharides in preventing experimental intraabdominal sepsis in the absence of antimicrobial therapy and may represent a new adjunct to antibiotic regimens currently used to prevent clinical cases of this disease.
Bacterial contamination of the abdominal cavity usually octhat predominate in experimental intraabdominal sepsis [3 -6] .
Facultative species, such as Escherichia coli, predominate in curs after perforation of the large bowel due to penetrating trauma to the abdomen, as a complication subsequent to abthe septic phase of disease and are associated primarily with mortality, while anaerobes, such as Bacteroides fragilis, are dominal surgery, or as a result of underlying bowel disease. Numerous clinical and experimental studies have shown that associated with abscess formation. In addition, a synergistic relationship between facultative and obligate anaerobes was the release of colonic contents into the peritoneal cavity can lead to widespread septicemia and/or the formation of intraabdefined that suggested that sepsis and abscess formation associdominal abscess(es) [1 -3] . The advent of prophylactic or theraated with this disease process was mediated, at least in part, peutic treatment with antimicrobial agents with activity against by the interaction of these bacterial species [6 -10] . both the facultative and obligate anaerobic components of the Previous studies have established the efficacy of soluble intestinal flora has greatly reduced the infection rate associated polymers of poly-(1-6)-b-glucotriosyl-(1-3)-b-glucopyranose with intraabdominal sepsis. However, despite appropriate treat-(PGG)-glucan (Betafectin; Alpha-Beta Technology, Worcester, ment with antibiotics, a significant number of abdominal infec-MA), a biologic response modifier, in prophylactic protection tions still occur in the clinical setting. Abdominal surgery and against bacteremia and mortality associated with experimenpostoperative wound infection rates range from 10% to 20%, tally induced peritonitis in rodent models [7, 9] . In these studwhile the incidence of abscesses in patients is 1% -4% [1] .
ies, prophylactic treatment with PGG-glucan yielded enhanced The failure of antimicrobial therapy in these cases may be clearance of bacteria from the peritoneal cavities of rats and attributable to many factors, including the emergence of antibiincreased total leukocyte counts. Protection against sepsis in otic-resistant bacteria and poor penetration of these agents this model was mediated, at least in part, by the induction of within the abdominal cavity.
prostaglandin production [9] . Previous studies in a rat model of intraabdominal sepsis have Work with the capsular polysaccharide complex of B. fragilis documented the role of particular intestinal bacterial species has demonstrated the importance of this virulence factor in regulating intraabdominal abscess formation in the rat model [11 -14] . Further studies have shown that the positively and negatively charged groups associated with the two component perforation, such as in patients with underlying bowel disease, B. fragilis PS A was prepared as previously described [11, 16, diverticulitis, appendicitis, and penetrating abdominal trauma 17] . PS A was prepared in sterile, pyrogen-free saline, and desig- [15] . To date, no compounds other than antibiotics have been nated doses were administered to animals by the subcutaneous used in experimental models to successfully prevent both route according to treatment regimens (see Results). In all experiphases of this disease process, and little is known regarding ments, a group of animals was treated with the saline vehicle used the therapeutic usefulness of these immunomodulators.
for polysaccharide treatment and served as the negative control.
Quantitative peritoneal fluid cultures. Peritoneal fluid was ob-
In the present study, we investigated the use of PGG-glucan 
Materials and Methods
Animal model for intraabdominal sepsis and challenge inocula. An animal model for intraabdominal sepsis was used for these nation of the two compounds before and after challenge with In studies to assess protection against B. fragilis -induced abscesses, an axenic culture of B. fragilis NCTC 9343 (10treated control group (30% vs. 60%; P õ .005). Delay of PGGglucan treatment ú4 h after challenge failed to protect animals against mortality associated with cecal contents challenge. In addition, increasing the concentration of PGG-glucan from 100 mg to 400 mg/dose failed to enhance the protection against mortality in these experiments (data not shown).
To determine whether PS A therapy could protect against abscess formation induced by the cecal contents inoculum, animals were challenged and treated with 50 mg of PS A 1, 24, 48, and 96 h after surgery. Results from these experiments showed that significantly fewer animals developed abscesses in the PS A -treated group than in the saline group (25% vs. 84%; P õ .001).
Delayed therapeutic protection against abscess formation by PS A. The chronic phase of intraabdominal sepsis, abscess formation, requires a period of §5 days after challenge to develop in the rat model. This period of time allowed for the opportunity to intervene with multiple doses of PS A after challenge and before the development of abscesses. In initial experiments, animals were challenged with B. fragilis to produce only the abscess phase of disease and given three different PS A regimens (designated in figure 2). The first regimen delayed the onset of therapeutic treatment by 1 h after challenge, while the second and third regimens delayed the onset of PS A treatments by 24 h or 48 h, respectively. While delaying PS A treatment for 1 h or 24 h after challenge with B. fragilis still induced significant protection against abscess formation, were treated prophylactically with PGG-glucan (048, 024, 04, and Animals given PS A treatment 1 or 24 h after challenge had /4 h relative to challenge) and/or PS A (024, /1, /24, and /72 h significantly lower abscess rates of 21% and 40%, respectively, relative to challenge) and challenged with rat cecal contents inoculum. A, Mortality rates in groups of animals treated with PGG-glucan, PS A, or combination. Combination treatment induced highest level of protection. * P õ .05; ** P õ .002 vs. saline-treated control, Fisher's exact test. B, Abscess formation rates in groups of animals treated with PGG-glucan, PS A, or combination. Treatment with both PGGglucan and PS A induced highest level of protection. * P õ .001; ** P õ .001 vs. saline-treated control, Fisher's exact test.
(figure 1B). Treatment with PS A alone resulted in a significant reduction in abscess formation compared with the saline-treated control group (38% vs. 100%; P Å .001), while treatment with PGG-glucan alone lowered the abscess rate to 84%, a reduction that was not statistically significant. Treatment with the combination of PGG-glucan and PS A was the most effective regimen, reducing the incidence of abscesses to 30% (P õ .001 compared with the saline-treated control group; P õ .001 compared with the PGG-glucan -treated group). with PGG-glucan had a lower mortality rate than did the saline-/ 9d4a$$jy18 05-27-98 00:26:31 jinfa UC: J Infect cultures were taken from PS A -and saline-treated animals at 24, 72, 96, and 120 h after challenge, and the total count of organisms was determined. B. fragilis persisted within the peritoneal cavities of saline-treated animals at Ç10 7 cfu/mL until 120 h after challenge, when bacterial counts declined to 10 5.97 cfu/mL ( figure 4A ). In contrast, there was enhanced bacterial clearance in the PS A -treated rats: Bacterial counts were lower than in saline-treated animals at 72 and 96 h after challenge and significantly reduced to 10 3.92 cfu/mL 120 h after challenge ( figure 4A ).
To extend these findings, we did similar experiments to determine the effect of PS A treatment on the clearance of aerobic and anaerobic bacteria from the peritoneal cavities of rats after challenge with the cecal contents inoculum. Animals were treated prophylactically with PS A (50 mg/dose) and challenged counts in both saline-and PS A -treated animals declined
Holding animals for this additional length of time does not affect their ability to form abscesses with dose of B. fragilis used. Animals within the first 24 h after challenge, were increased at 72 and were then examined for abscess formation 6 days after challenge.
96 h after challenge, and declined again at 120 h after challenge Animals challenged at day 0, 2, 6, and 13 had significantly fewer (figures 4B, C). Although there were no significant differences abscesses than saline-treated controls, while animals challenged 20 in total number of aerobes or anaerobes between saline-and days later were not protected. * P õ .005, Fisher's exact test.
PS A -treated animals at the 24, 72, or 96 h time points, there were significant differences in PS A -treated animals 120 h after challenge. The number of total aerobes in saline-treated compared with 100% in the saline-treated control group. The delay of PS A treatment for 48 h after challenge yielded an animals at this time point was 10 3.6 cfu/mL, compared with 10 2.15 cfu/mL in PS A -treated animals ( figure 4B ; P õ .05). abscess rate of 86%.
Duration of protective activity by PS A.
To determine the The total number of anaerobes found in saline-treated animals at this time point was 10 5.3 cfu/mL, while the number of anaerduration of the protective activity of PS A, animals were given a three-dose regimen of the polysaccharide (10 mg/dose) and obes found in PS A -treated animals was below the limit of detection (õ10 2 cfu/mL) for this assay ( figure 4C ). challenged at various times after the final dose of polysaccharide (0, 2, 6, 13, or 20 days after treatment). We have previously established that holding animals for this additional length of Discussion time does not affect their ability to form abscesses with the dose of B. fragilis used. Results are shown in figure 3 . All
Because of the emergence of antibiotic-resistant bacteria and the continued incidence of postsurgical infections associsaline-treated animals formed one or more intraabdominal abscesses, while animals treated with the last dose of PS A at ated with high-risk abdominal procedures, investigators have begun to identify potential compounds that could augment the time of challenge had a 24% abscess rate (P õ .001). Groups of animals challenged 2, 6, and as long as 13 days standard antibiotic regimens currently used in these cases. In this study, we evaluated the use of two immunomodulatory after the final PS A treatment had significantly lower abscess rates compared with the saline-treated control group (P õ polysaccharides for the prevention of experimental intraabdominal sepsis. .005). In contrast, animals challenged 20 days after the last dose of PS A were not protected against abscess formation
We first evaluated the prophylactic use of PGG-glucan and PS A alone and in combination for their ability to reduce the (80% abscess rate).
Bacterial clearance from the peritoneal cavity of PS Aincidence of both mortality and abscess formation associated with experimental intraabdominal sepsis. This inoculum is pretreated animals. To investigate whether the prevention of abscesses by PS A in this model could be related to the enpared from meat-fed rats and closely approximates the microflora of human intestinal contents [3] . Intraperitoneal challenge with hancement of bacterial clearance from the peritoneal cavities of rats, bacterial counts were done on peritoneal fluid cultures rat cecal contents simulates the release of human colonic contents into the abdominal cavity following rupture or leakage of of animals challenged with monomicrobial or polymicrobial inocula. Initially, animals were prophylactically treated with the bowel. The results of these experiments clearly demonstrate that combination treatment with the two immunomodulating PS A (10 mg/dose) at 024, /1, /24, /48, and /72 h relative to challenge with B. fragilis (10 8 cfu/animal). Peritoneal fluid polysaccharides was the best regimen for the prevention of both / 9d4a$$jy18 05-27-98 00:26:31 jinfa UC: J Infect Treatment with PS A yielded significant reduction in bacterial counts 120 h after challenge compared with saline-treated controls. * P õ .05, Student's t test (unpaired). B, C, Quantitative aerobic and anaerobic cultures, respectively, from rat cecal contents challenge. Animals were treated with PS A (50 mg/dose) at 024, /1, /24, /48, and /72 h relative to challenge with rat cecal contents. Cultures of freeflowing peritoneal exudates were taken from anesthetized animals 24, 72, 96, and 120 h after challenge. Bacterial count at 0-h time point represents no. of organisms present in challenge inoculum. Treatment with PS A yielded significant reduction in aerobic bacterial counts 120 h after challenge compared with saline-treated controls and reduced no. of anaerobic organisms in peritoneal fluid of treated animals to below detection limit for this assay (10 2 cfu/mL). * P õ .05, Student's t test (unpaired).
phases of experimental intraabdominal sepsis. These data demTherefore, we investigated the potential of using each of these compounds in the therapeutic mode to ascertain their effect on onstrated that PGG-glucan was most effective in preventing mortality, while PS A was most effective in reducing the incidence each phase of intraabdominal sepsis. Experiments with PGGglucan showed that it could be administered a short time (4 h) of abscess formation. It was interesting to note that PGG-glucan and PS A had some crossover activity in reducing abscess formaafter challenge with cecal contents and still induce a protective response in animals. These results were surprising, given the tion and mortality, respectively, but the level of reduction was not statistically significant in either case. Although a number of fact that the onset of sepsis in this model is rapid and severe, with most animals dying 18 -24 h after challenge. It is likely biologics, such as monoclonal antibodies, cytokines, and receptor antagonists, have been tested to reduce the incidence of sepsis that PGG-glucan induces a rapid immunomodulatory effect that adequately dampens the septic phase of the disease process. in animal models and clinical trials, this is the first example of compounds other than antibiotics that can be successfully used Delay of the administration of PGG-glucan beyond this time failed to elicit protection, indicating that while a protective to lower the incidence of both mortality and abscess formation in experimental intraabdominal sepsis.
response most likely occurs within a short period of time, the onset of frank sepsis can overwhelm this protective effect in It is clear that the highest risk of postoperative infections occurs in patients with unexpected bowel perforation, such the absence of antibiotic therapy. Further studies are underway to assess the use of PGG-glucan treatment as an adjunct to as in cases of penetrating abdominal trauma, appendicitis, or diverticulitis or after development of underlying disease [15] .
antibiotic therapy in these cases. Studies with PS A were then done to ascertain its use-1 -2 days before the time when fully formed abscesses are found in similarly challenged saline-treated or untreated anifulness when used in the therapeutic mode for the prevention of intraabdominal abscesses. Previous studies had indicated mals. It is possible that PS A suppresses host factors that lead to the development of abscesses and results in improved that PS A could be used in a therapeutic mode to protect against monomicrobial challenge with B. fragilis [11] . Howmechanical clearance of the bacterial load via the diaphragmatic lymph system present in the peritoneal cavity. ever, it was unclear whether this compound could be used in a setting that more closely approximated the clinical situa-A number of studies have documented the immunomodulatory properties of soluble glucans in protecting against experition, in which peritoneal soilage is caused by the release of several hundred bacterial species into the abdomen. In these mentally induced peritonitis [7, 9, 18, 19] . These studies have focused mainly on the effects of prophylactic administration studies, PS A could be administered as late as 24 h after challenge with cecal contents and still protect against abscess of these compounds on the acute phase of peritonitis but have not assessed the ability of this compound to prevent abscess formation. This protective activity was lost when administration was delayed to 48 h after challenge. These data supformation associated with this disease process. Studies suggest that the protective effect of PGG-glucan is related to its ability ported our belief that therapeutic protection against abscess formation was possible in the animal model, as this pathoto potentiate or prime the microbicidal activities of leukocytes [20] . In addition, protection against lethal challenge in the rat logic host response takes at least 4 -5 days to form. In contrast to the rapid onset of sepsis in this model, the prolonged model has been shown to involve production of antiinflammatory mediators such as prostaglandins [9] . In contrast, B. fragformation of abscesses in rats provides ample time for the commencement of therapeutic intervention for the prevenilis PS A has only recently been described as an immunomodulating polysaccharide, and little is known about its protective tion of this host response. Given the fact that abscess formation in people also occurs as a chronic infection over an activity. Previous studies in rats have shown that the protective activity conferred by PS A is mediated by T cells [11, 14] . We extended period of time, the window of opportunity for therapeutic intervention with PS A exists, and successful therapy are currently investigating the interaction of PS A with this lymphocyte and the role of this interaction with abscess prevencould be possible.
We next examined the length of time PS A -mediated tion. In summary, these data suggest that the combined use of protection persisted in animals after the last dose of polysaccharide administered. The finding that this protective activity PGG-glucan and PS A could lower infection rates associated with abdominal surgeries. The use of immunomodulatory comlasted for as long as 2 weeks after the final dose indicated that PS A may have long-lived biologic effects. This finding pounds that enhance the host's ability to combat infections represents a change from conventional antiinfective strategies contrasts with previous results with PGG-glucan in rodent models. The protective activity of this polysaccharide is that have relied solely on direct bactericidal activities of drug compounds. This approach would also be advantageous in short-lived and depends on repeated administration to animals [7] . Whether the long-lived effects of PS A are due to cases involving antibiotic-resistant organisms and could be useful as an adjunct to standard antimicrobial therapy in intraablimited clearance from the circulating lymph system or the induction of a lasting immune response is not known. We dominal sepsis as well as other infectious processes. Further work is being done to better understand the mechanisms by are currently investigating the pharmacokinetics of PS A distribution in animals.
which these compounds interact with the host immune system to induce these protective effects. Previous work with PGG-glucan has shown that the mechanism of protection is related in part to its ability to enhance bacterial clearance from treated animals after intraperitoneal challenge with rat cecal contents [7] . In these experiments,
